CCL5 and rheumatoid arthritis: However, inhibiting the glycolytic pathway, using small molecule inhibitor 3‐(3‐pyridinyl)‐1‐(4‐pyridinyl)‐2‐propen‐1‐one (3PO), resulted in reducing TLR2‐induced RA synovial fibroblast invasion and migration and attenuated pro‐inflammatory cytokines IL‐6, IL‐8, MCP‐1 and RANTES production [39].